Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ZLTQ's Cash-to-Debt is ranked higher than
84% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.87 vs. ZLTQ: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ZLTQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 228.04 Max: No Debt
Current: No Debt
Equity-to-Asset 0.64
ZLTQ's Equity-to-Asset is ranked higher than
50% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ZLTQ: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
ZLTQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -9.69  Med: 0.69 Max: 0.89
Current: 0.64
-9.69
0.89
Interest Coverage 236.14
ZLTQ's Interest Coverage is ranked higher than
59% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. ZLTQ: 236.14 )
Ranked among companies with meaningful Interest Coverage only.
ZLTQ' s Interest Coverage Range Over the Past 10 Years
Min: 236.14  Med: No Debt Max: No Debt
Current: 236.14
Piotroski F-Score: 4
Altman Z-Score: 19.42
Beneish M-Score: -2.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 3.73
ZLTQ's Operating Margin % is ranked higher than
53% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. ZLTQ: 3.73 )
Ranked among companies with meaningful Operating Margin % only.
ZLTQ' s Operating Margin % Range Over the Past 10 Years
Min: -1082.23  Med: -15.05 Max: 3.73
Current: 3.73
-1082.23
3.73
Net Margin % 0.20
ZLTQ's Net Margin % is ranked lower than
53% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. ZLTQ: 0.20 )
Ranked among companies with meaningful Net Margin % only.
ZLTQ' s Net Margin % Range Over the Past 10 Years
Min: -1111.78  Med: -15.69 Max: 16.37
Current: 0.2
-1111.78
16.37
ROE % 0.57
ZLTQ's ROE % is ranked lower than
52% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ZLTQ: 0.57 )
Ranked among companies with meaningful ROE % only.
ZLTQ' s ROE % Range Over the Past 10 Years
Min: -299.73  Med: -14.02 Max: 42.91
Current: 0.57
-299.73
42.91
ROA % 0.37
ZLTQ's ROA % is ranked higher than
52% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.11 vs. ZLTQ: 0.37 )
Ranked among companies with meaningful ROA % only.
ZLTQ' s ROA % Range Over the Past 10 Years
Min: -254.68  Med: -18.49 Max: 29.57
Current: 0.37
-254.68
29.57
ROC (Joel Greenblatt) % 45.69
ZLTQ's ROC (Joel Greenblatt) % is ranked higher than
83% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.41 vs. ZLTQ: 45.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZLTQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1427.33  Med: -444.68 Max: 45.69
Current: 45.69
-1427.33
45.69
3-Year Revenue Growth Rate 40.50
ZLTQ's 3-Year Revenue Growth Rate is ranked higher than
94% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. ZLTQ: 40.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ZLTQ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -22.3 Max: 41.9
Current: 40.5
-68.6
41.9
GuruFocus has detected 4 Warning Signs with ZELTIQ Aesthetics Inc ZLTQ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZLTQ's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ZLTQ Guru Trades in Q3 2016

Paul Tudor Jones 5,947 sh (New)
Jim Simons 161,600 sh (+251.99%)
Chuck Royce 108,000 sh (+33.33%)
Columbia Wanger 412,602 sh (-22.62%)
Steven Cohen 797,696 sh (-64.06%)
» More
Q4 2016

ZLTQ Guru Trades in Q4 2016

Joel Greenblatt 21,960 sh (New)
Paul Tudor Jones 31,742 sh (+433.75%)
Jim Simons 372,100 sh (+130.26%)
Chuck Royce 125,000 sh (+15.74%)
Columbia Wanger 248,042 sh (-39.88%)
Steven Cohen 125,506 sh (-84.27%)
» More
Q1 2017

ZLTQ Guru Trades in Q1 2017

Mario Gabelli 327,982 sh (New)
Caxton Associates 4,900 sh (New)
Chuck Royce Sold Out
Steven Cohen Sold Out
Columbia Wanger Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 22,054 sh (-30.52%)
Jim Simons 154,900 sh (-58.37%)
» More
Q2 2017

ZLTQ Guru Trades in Q2 2017

Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Sold Out 0.12%$55.61 - $56.5 $ 56.480%0
Mario Gabelli 2017-03-31 New Buy0.12%$40.71 - $55.93 $ 56.4813%327,982
Joel Greenblatt 2017-03-31 Sold Out 0.01%$40.71 - $55.93 $ 56.4813%0
Joel Greenblatt 2016-12-31 New Buy0.01%$32.42 - $45.76 $ 56.4840%21,960
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:TSE:8086, SZSE:300529, NAS:INGN, XSWX:TECN, OCSE:OSSR, XSWX:YPSN, TSE:6849, TSE:7575, NYSE:NVRO, NAS:WMGI, NAS:SPNC, NAS:NUVA, NYSE:ITGR, XTER:DRW3, NYSE:GMED, TSE:3360, SZSE:300633, NYSE:PEN, NAS:CNMD, SZSE:002317 » details
Headquarter Location:USA
ZELTIQ Aesthetics Inc is a medical technology company. The Company is engaged in developing and commercializing products utilizing its proprietary controlled cooling technology platform.

ZELTIQ Aesthetics Inc was incorporated in Delaware in March 2005 as Juniper Medical, Inc. In July 2007, it changed its name to ZELTIQ Aesthetics, Inc. ZELTIQ Aesthetics, Inc. is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled cooling technology platform. Its first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.

Top Ranked Articles about ZELTIQ Aesthetics Inc

PBF Energy Set to Join S&P MidCap 400; Apollo Commercial Real Estate Finance and Waddell & Reed Financial to Join S&P SmallCap 600
Allergan and ZELTIQ Announce Expiration of Hart-Scott-Rodino Waiting Period for Pending Transaction
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against ZELTIQ Aesthetics, Inc.
CoolSculpting® and Debra Messing Partner to Inspire Confidence and Cool Moments
ZELTIQ® Showcases CoolAdvantage Petite™ Applicator for the CoolSculpting® System at American Academy of Dermatology Annual Meeting

CoolSculpting is Only Non-Invasive Fat Removal Technology FDA-Cleared to Treat Upper Arms

PLEASANTON, Calif., March 03, 2017 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (NASDAQ:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced it is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando, Fla.  The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the Food and Drug Administration (FDA) to address the upper arm.
Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8d9d53d2-4730-40b2-bad3-d3560106fb41 http://www.globenewswire.com/NewsRoom/AttachmentNg/5f490a53-531c-4ac6-8c13-ff3a5c14d0d8 “After 5 years of research and millions of dollars invested in development, we are proud to be the only non-invasive fat reduction technology that is FDA-cleared to treat the upper arms, the third greatest area of concern for consumers,” said Mark Foley, President and Chief Executive Officer of ZELTIQ.  “Through direct-to-consumer advertising, we plan to raise awareness around this new treatment area and help drive consumers to our customers’ CoolSculpting practices.” The newest member of the CoolAdvantage family of applicators, the CoolAdvantage Petite, treats the upper arm in just 35 minutes and comes with two interchangeable contours customized to treat the unique shape of the upper arm area.  The commercial release of the CoolAdvantage Petite applicator is planned for the middle part of 2017. “The upper arm, with its delicate structures, is one of the most challenging areas for fat reduction,” said Jean Carruthers, MD, FRCSC, FRC(OPHTH), of Carruthers & Humphrey Cosmetic Dermatology in Vancouver, Canada.  “As one of the principal investigators for the CoolAdvantage Petite applicator, I can attest to the fact that the upper arms responded beautifully and my study patients are delighted by their results.” Providers attending AAD who want to learn more about the CoolSculpting procedure and CoolAdvantage Petite applicator can visit CoolSculpting Booth #1231 in the Orange County Convention Center during exhibit hours 10 a.m. to 5 p.m. March 3-4, and 10 a.m. to 3 p.m. on March 5.  You can also learn more by visiting www.coolsculptinghcp.com. With more than 70 peer-reviewed clinical papers and abstracts and over 4 million treatments performed to date in over 80 countries around the world, CoolSculpting is clinically proven to be a safe and effective treatment for non-invasive fat reduction.  CoolSculpting is FDA-cleared to affect the appearance of fat bulges in the upper arm, bra and back fat, banana roll, submental area, thigh, abdomen and flank. CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.   About the CoolSculpting® Procedure
CoolSculpting is a non-surgical, clinically proven procedure that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting works by gently cooling targeted fat cells to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good.  Millions of CoolSculpting treatments have been performed by more than 5,700 CoolSculpting systems in over 80 countries. Market research indicates up to a 95 percent customer satisfaction rate with the CoolSculpting procedure. CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com. Be sure to follow CoolSculpting on Facebook, Twitter, Pinterest and YouTube. About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform.  ZELTIQ’s first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges.  CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.  It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis.  ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer. Forward-Looking Statements
The statements made in this press release regarding ZELTIQ's expectations for the performance of the CoolAdvantage Petite and its ability to drive people to its customers’ practices to ask for CoolSculpting by name are forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond ZELTIQ's control and that could materially affect ZELTIQ's actual business operations. Factors that could materially affect ZELTIQ's business operations include, but are not limited to, risks and uncertainties set forth in ZELTIQ's Quarterly Report on Form 10-Q for the year ended December 31, 2016, filed with the SEC on March 1, 2017. These forward-looking statements speak only as of the date of this press release. ZELTIQ expressly disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or otherwise.
MEDIA CONTACT:                              
Jill Knepper
Ketchum for ZELTIQ
310-437-2517                               

INVESTOR RELATIONS:
Taylor Harris
ZELTIQ, Senior Vice President and CFO
925-474-2500

Nick Laudico
The Ruth Group for ZELTIQ
646-536-7030

Read more...

Ratios

vs
industry
vs
history
PE Ratio 5648.00
ZLTQ's PE Ratio is ranked lower than
100% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. ZLTQ: 5648.00 )
Ranked among companies with meaningful PE Ratio only.
ZLTQ' s PE Ratio Range Over the Past 10 Years
Min: 1.09  Med: 56.48 Max: 5650
Current: 5648
1.09
5650
Forward PE Ratio 178.57
ZLTQ's Forward PE Ratio is ranked lower than
91% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ZLTQ: 178.57 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 5648.00
ZLTQ's PE Ratio without NRI is ranked lower than
100% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 27.81 vs. ZLTQ: 5648.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZLTQ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.09  Med: 56.48 Max: 5650
Current: 5648
1.09
5650
PB Ratio 16.47
ZLTQ's PB Ratio is ranked lower than
94% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ZLTQ: 16.47 )
Ranked among companies with meaningful PB Ratio only.
ZLTQ' s PB Ratio Range Over the Past 10 Years
Min: 1.79  Med: 10.14 Max: 19.15
Current: 16.47
1.79
19.15
PS Ratio 6.47
ZLTQ's PS Ratio is ranked lower than
73% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. ZLTQ: 6.47 )
Ranked among companies with meaningful PS Ratio only.
ZLTQ' s PS Ratio Range Over the Past 10 Years
Min: 0.16  Med: 4.6 Max: 7.94
Current: 6.47
0.16
7.94
Price-to-Free-Cash-Flow 252.14
ZLTQ's Price-to-Free-Cash-Flow is ranked lower than
96% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 28.08 vs. ZLTQ: 252.14 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZLTQ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 82.3  Med: 199.49 Max: 4204.44
Current: 252.14
82.3
4204.44
Price-to-Operating-Cash-Flow 141.55
ZLTQ's Price-to-Operating-Cash-Flow is ranked lower than
96% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 19.79 vs. ZLTQ: 141.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZLTQ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 58.67  Med: 131.99 Max: 245.71
Current: 141.55
58.67
245.71
EV-to-EBIT 165.69
ZLTQ's EV-to-EBIT is ranked lower than
95% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 23.37 vs. ZLTQ: 165.69 )
Ranked among companies with meaningful EV-to-EBIT only.
ZLTQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -1381.5  Med: -5.1 Max: 644.5
Current: 165.69
-1381.5
644.5
EV-to-EBITDA 130.03
ZLTQ's EV-to-EBITDA is ranked lower than
94% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 17.75 vs. ZLTQ: 130.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZLTQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -372.2  Med: -4.5 Max: 877.6
Current: 130.03
-372.2
877.6
EV-to-Revenue 6.19
ZLTQ's EV-to-Revenue is ranked lower than
70% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. ZLTQ: 6.19 )
Ranked among companies with meaningful EV-to-Revenue only.
ZLTQ' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 4.5 Max: 7.8
Current: 6.19
0.1
7.8
Current Ratio 2.27
ZLTQ's Current Ratio is ranked lower than
58% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. ZLTQ: 2.27 )
Ranked among companies with meaningful Current Ratio only.
ZLTQ' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.48 Max: 8.26
Current: 2.27
0.63
8.26
Quick Ratio 1.75
ZLTQ's Quick Ratio is ranked lower than
54% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ZLTQ: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
ZLTQ' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.01 Max: 7.87
Current: 1.75
0.52
7.87
Days Inventory 112.10
ZLTQ's Days Inventory is ranked higher than
62% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 139.39 vs. ZLTQ: 112.10 )
Ranked among companies with meaningful Days Inventory only.
ZLTQ' s Days Inventory Range Over the Past 10 Years
Min: 46.43  Med: 104.98 Max: 163.22
Current: 112.1
46.43
163.22
Days Sales Outstanding 56.95
ZLTQ's Days Sales Outstanding is ranked higher than
69% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 67.97 vs. ZLTQ: 56.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZLTQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.79  Med: 39.55 Max: 237.12
Current: 56.95
8.79
237.12
Days Payable 59.71
ZLTQ's Days Payable is ranked higher than
50% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ZLTQ: 59.71 )
Ranked among companies with meaningful Days Payable only.
ZLTQ' s Days Payable Range Over the Past 10 Years
Min: 42.46  Med: 64.29 Max: 144.83
Current: 59.71
42.46
144.83

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
ZLTQ's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: -4.90 vs. ZLTQ: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZLTQ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -453  Med: -3.9 Max: -2.7
Current: -2.7
-453
-2.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 25.56
ZLTQ's Price-to-Net-Current-Asset-Value is ranked lower than
86% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. ZLTQ: 25.56 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ZLTQ' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.36  Med: 16.59 Max: 25.56
Current: 25.56
3.36
25.56
Price-to-Tangible-Book 17.01
ZLTQ's Price-to-Tangible-Book is ranked lower than
87% of the 274 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. ZLTQ: 17.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ZLTQ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.54  Med: 10.94 Max: 17.02
Current: 17.01
2.54
17.02
Price-to-Intrinsic-Value-Projected-FCF 54.31
ZLTQ's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 2.26 vs. ZLTQ: 54.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZLTQ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 41.85  Med: 224.71 Max: 407.57
Current: 54.31
41.85
407.57
Price-to-Median-PS-Value 1.41
ZLTQ's Price-to-Median-PS-Value is ranked lower than
72% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. ZLTQ: 1.41 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZLTQ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.03 Max: 1.41
Current: 1.41
0.08
1.41
Price-to-Graham-Number 65.67
ZLTQ's Price-to-Graham-Number is ranked lower than
100% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ZLTQ: 65.67 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ZLTQ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.42  Med: 22.88 Max: 65.67
Current: 65.67
3.42
65.67
Earnings Yield (Greenblatt) % 0.60
ZLTQ's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.94 vs. ZLTQ: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZLTQ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3715.7  Med: -1.6 Max: 311.7
Current: 0.6
-3715.7
311.7

More Statistics

Revenue (TTM) (Mil) $354.20
EPS (TTM) $ 0.01
Short Percentage of Float4.96%
52-Week Range $23.58 - 56.50
Shares Outstanding (Mil)40.42

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 417 482
EPS ($) 0.32 0.82
EPS without NRI ($) 0.32 0.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}